For developers, success depends on more than promising clinical data. A strong Cell & Gene Therapy CMC & Regulatory strategy must connect product development, manufacturing, quality systems, clinical planning, and regulatory submissions from the earliest stages. The right approach can help sponsors identify regulatory expectations sooner, reduce costly rework, and create a clearer path from an IND Application toward marketing approval.

BioNetwork Consulting supports life sciences organizations with regulatory, compliance, Computer System Validation (CSV), and specialized consulting expertise designed to help companies navigate highly regulated development environments.

What Cell and Gene Therapies Are and Why They Are Complex to Regulate

Cell and gene therapies are advanced therapeutic products that use cells, genetic material, or both to achieve a therapeutic effect. Unlike many conventional pharmaceuticals, their biological characteristics can be closely connected to the manufacturing process itself.

Cell therapies may involve collecting, modifying, expanding, and administering human cells. Gene therapies may use genetic material to modify cellular function, replace a defective gene, or introduce a new biological activity. Some products combine multiple sophisticated technologies and manufacturing steps.

This complexity creates regulatory challenges across the entire product lifecycle.

Developers must demonstrate that the product is appropriately characterized, manufactured consistently, and controlled for identity, purity, potency, safety, and other critical quality attributes. The relationship between manufacturing processes and product performance also makes process changes particularly important.

For this reason, regulatory planning should begin well before an IND submission. Sponsors need a strategy that considers CMC development, nonclinical requirements, clinical development, manufacturing controls, data integrity, documentation, and long-term regulatory expectations.

FDA Regulatory Pathways — BLA, Accelerated Approval, and RMAT Designation

The FDA regulatory pathway for a cell or gene therapy depends on factors such as the product’s characteristics, intended use, clinical evidence, and development stage.

For many biological products, the Biologics License Application (BLA) represents the marketing application through which a sponsor seeks FDA approval. The BLA brings together extensive information covering manufacturing, quality, nonclinical studies, clinical studies, facilities, and regulatory compliance.

Some products may also qualify for programs intended to support development of therapies addressing serious conditions and unmet medical needs.

Accelerated Approval can provide a pathway for certain serious or life-threatening conditions when specific regulatory criteria are met. The pathway may allow approval based on a surrogate endpoint that is reasonably likely to predict clinical benefit, with appropriate requirements for post-approval confirmation.

The Regenerative Medicine Advanced Therapy (RMAT) designation is another important consideration for qualifying regenerative medicine therapies. RMAT can provide opportunities for increased interaction with the FDA and potentially facilitate development and review planning.

Understanding these pathways early allows sponsors to make better decisions about development milestones, evidence generation, regulatory interactions, and submission planning.

CMC Requirements for CGT Products — Manufacturing, Quality Control, and Characterisation

CMC is one of the most important components of cell and gene therapy development.

Chemistry, Manufacturing, and Controls (CMC) information must provide regulators with confidence that the product can be consistently manufactured and appropriately controlled for its intended use.

For CGT developers, CMC planning can involve several critical areas.

Manufacturing Process

Manufacturing processes should be designed with consistency, scalability, and product quality in mind. Sponsors may need to evaluate raw materials, starting materials, manufacturing steps, equipment, process parameters, facilities, and aseptic processing considerations.

For autologous products, manufacturing may be particularly complex because each patient’s material can represent an individual manufacturing starting point. Chain-of-identity and chain-of-custody considerations can therefore become critical.

Quality Control

A robust quality control strategy helps demonstrate that manufactured products meet established specifications.

Depending on the product, testing may address attributes such as identity, purity, potency, viability, sterility, endotoxin, mycoplasma, residual materials, and other relevant characteristics.

The appropriate analytical strategy should be scientifically justified and aligned with the product’s mechanism of action and risk profile.

Product Characterisation

Characterisation helps sponsors understand the product and establish meaningful quality attributes.

For gene therapy products, this can involve evaluating characteristics associated with the vector, genetic material, biological activity, impurities, and other product-specific attributes. For cell-based therapies, characterization may include cell identity, phenotype, viability, potency, and other relevant properties.

CMC development should not be treated as a documentation exercise performed immediately before submission. It should evolve alongside product and process development.

Common CGT Regulatory Challenges in 2026

Cell and gene therapy developers continue to face several practical challenges.

One major challenge is process consistency. Small changes in manufacturing can potentially affect product characteristics, making process understanding essential.

Another challenge is potency testing. Establishing an assay that appropriately reflects the biological activity or mechanism of action can be technically difficult for innovative therapies.

Analytical method development and validation can also require significant planning. Sponsors need reliable methods that support product characterization, release testing, stability programs, and regulatory expectations.

Manufacturing scale-up presents another challenge. A process that works during early development may require substantial optimization before commercial manufacturing.

Sponsors must also consider comparability when manufacturing processes, facilities, equipment, raw materials, or analytical methods change. Demonstrating that a change has not adversely affected product quality can become an important regulatory consideration.

In addition, CGT programs must manage extensive documentation and data throughout development. Strong quality systems, validated computerized systems, and reliable data integrity practices are essential in highly regulated environments.

How to Build a CGT Regulatory Strategy From IND Through BLA

A successful Regulatory Strategy & Submissions should be established early rather than assembled immediately before a submission.

The process can begin with defining the product profile, development objectives, target indication, and regulatory pathway. Sponsors can then map the evidence required to support an IND Application, including CMC, nonclinical, clinical, and supporting documentation.

A practical regulatory strategy can include:

• Defining regulatory milestones and submission timelines
• Establishing CMC development priorities
• Identifying critical quality attributes and process parameters
• Developing appropriate analytical and potency strategies
• Preparing regulatory meeting objectives and briefing materials
• Evaluating FDA feedback and incorporating it into development plans
• Maintaining appropriate validation and quality documentation
• Preparing clinical and regulatory submission content
• Establishing a lifecycle strategy for manufacturing and process changes
• Planning the transition from IND development toward BLA requirements

The IND stage should establish a foundation for later development rather than focus exclusively on gaining authorization to begin clinical studies.

As development progresses, sponsors should continually assess whether their CMC strategy, clinical evidence, manufacturing controls, and regulatory documentation remain aligned with the requirements for a future BLA.

This integrated approach can help reduce disconnects between development teams and regulatory teams.

How BioNetwork Consulting Supports Life Sciences Organizations

BioNetwork Consulting helps pharmaceutical, biotechnology, and medical device organizations navigate complex regulatory and operational environments.

Its expertise includes regulatory strategy, Computer System Validation (CSV), quality assurance, clinical talent recruitment, and life sciences consulting. By combining regulatory understanding with practical industry experience, BioNetwork Consulting helps organizations establish stronger frameworks for compliant development.

For cell and gene therapy programs, this type of integrated support can be particularly valuable when sponsors need to coordinate regulatory requirements, quality systems, technology, documentation, and specialized expertise.

BioNetwork Consulting works with organizations across different stages of the life sciences lifecycle, supporting companies as they move from development and clinical programs toward commercialization.

Building a Stronger Regulatory Foundation for the Future

Cell and gene therapy development is moving rapidly, but innovation alone does not guarantee regulatory success. Sponsors need a clear understanding of CMC expectations, regulatory pathways, clinical requirements, manufacturing controls, and submission strategy.

A well-planned Cell & Gene Therapy CMC & Regulatory program can help organizations identify risks earlier and establish a stronger foundation for regulatory interactions.

From the initial IND Application to long-term BLA planning, every stage should contribute toward demonstrating product quality, safety, consistency, and clinical value.

With the right regulatory strategy and specialized expertise, life sciences organizations can approach complex development programs with greater confidence while keeping compliance at the center of innovation.

BioNetwork Consulting brings together regulatory knowledge, CSV expertise, quality-focused consulting, and clinical talent solutions to help organizations move forward in today’s demanding life sciences environment.

Frequently Asked Questions

1. What is Cell & Gene Therapy CMC & Regulatory consulting?

Cell & Gene Therapy CMC & Regulatory consulting involves strategic support for manufacturing, quality, characterization, regulatory planning, submissions, and compliance activities associated with cell and gene therapy products. It helps sponsors align development activities with regulatory expectations.

2. What is an IND Application for a cell or gene therapy?

An Investigational New Drug (IND) application is submitted to the FDA to request authorization to begin clinical investigation of an investigational product in the United States. For CGT products, the submission generally requires appropriate information concerning manufacturing and controls, nonclinical studies, clinical protocols, and related regulatory information.

3. Why is CMC especially important for cell and gene therapies?

CMC is particularly important because the manufacturing process can have a significant relationship with the characteristics and performance of advanced therapy products. Sponsors need to establish appropriate manufacturing controls, analytical methods, specifications, and quality systems.

4. What is the difference between an IND and a BLA?

An IND supports authorization to conduct clinical investigations, while a BLA is a marketing application for a biological product seeking FDA approval. The development strategy should connect the information generated during the IND stage with the eventual requirements for marketing authorization.

5. What is RMAT designation?

RMAT is a designation available under certain conditions for qualifying regenerative medicine therapies intended to treat serious or life-threatening diseases or conditions. It can provide opportunities for increased FDA interaction and development support.

6. When should a CGT regulatory strategy be developed?

Regulatory strategy should ideally begin during early product development. Early planning allows sponsors to identify CMC, clinical, quality, and submission requirements before major development decisions are finalized.

7. How can regulatory consulting help with an IND Application?

Regulatory consulting can help sponsors organize submission strategies, assess development requirements, prepare regulatory documentation, identify potential gaps, and align CMC and clinical development activities with regulatory objectives.

8. Why are validated systems important in life sciences?

Validated computerized systems help organizations demonstrate that systems used in regulated processes operate as intended and support reliable, traceable, and compliant data. This is particularly important when systems support GxP-regulated activities.

Partner With BioNetwork Consulting

For organizations developing innovative therapies, regulatory compliance should be viewed as an integral part of innovation—not an obstacle to it.

BioNetwork Consulting helps life sciences companies bring together regulatory expertise, quality-focused processes, validated systems, and specialized talent to support development from early planning through commercialization.